News Related to Seborrheic Dermatitis

Phase III Clascoterone Data Shows Sustained Hair Growth; Scalp SD Metabolomics Reveals Key Inflammatory Markers

Jun 26, 2026

Cosmo Pharmaceuticals reported positive 12-month Phase III data for Clascoterone 5% topical solution in male androgenetic alopecia, showing sustained hair growth and a safety profile comparable to vehicle. A separate metabolomics study characterized key inflammatory markers in scalp seborrheic dermatitis, identifying Malassezia fungi and specific free fatty acids as central drivers of the condition.

Arcutis draws focus to Zoryve data, FDA filings and Q4 expectations

May 03, 2026

Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.

Arcutis Biotherapeutics to Report Q4 2025 Earnings on February 25

Feb 13, 2026

Arcutis Biotherapeutics is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. Investors will focus on sales performance of Zoryve and pipeline updates.